



Press Release

Louvain-la-Neuve, Belgium and Lalaye, France – June 23, 2020

MEDDRAYSINTELL NUCLEAR MEDICINE REPORT TO BE RELEASED IN SEPTEMBER

MEDDraysintell postpones the publication of its Nuclear Medicine Report & Directory Edition 2020, it will be available in September 2020, before the EANM congress.

Following the coronavirus pandemic situation and the cancellation of several nuclear medicine congresses such as the SNMMI, MEDDraysintell announces that its seventh Edition of the yearly Nuclear Medicine Report & Directory will be available this year with a delay of two months, in September 2020.

The Edition 2020 will be available in three volumes (over 2,500 pages), covering more than 750 products, including tracers and drugs on the market or under clinical or preclinical development. It is also providing an exhaustive profile of roughly 300 companies marketing or developing these products around the world.

- MEDDraysintell Nuclear Medicine (Part 1) - Marketed Radiopharmaceuticals
- MEDDraysintell Nuclear Medicine (Part 2) - Clinical Radiopharmaceuticals
- MEDDraysintell Nuclear Medicine (Part 3) - Early Stage Radiopharmaceuticals

MEDDraysintell estimates that the global market for nuclear medicine reached close to US\$ 6 billion in 2019, growing by approximately 8% from 2018. The progression has been slightly affected by exchange rate fluctuations of the major currencies against the US dollar. Without this exchange rate influence, MEDDraysintell estimates that the nuclear medicine market would have grown by more than 9% from 2018 to 2019. The radiotherapeutics have grown by 20% in 2019 from 2018. Microspheres are considered as a brachytherapy device, however due to the new regulations that are slowly being implemented regarding non-removable devices, microspheres as well as other "biosoluble" medical devices will be considered as medicinal products analogues, and MEDDraysintell decided to include those products into the nuclear medicine report.

For this year 2020, MEDDraysintell has already observed a slowdown of the nuclear medicine activity, consequence of the COVID-19 pandemic crisis. Air transport of radionuclides and radiopharmaceuticals has been the main bottleneck to distribute those products to hospitals. The situation is improving since end of May 2020, but this situation will definitely affect the 2020 figures.

MEDDraysintell will display its Nuclear Medicine reports and directories as well as its recently published Cyclotrons Report and Directory during the EANM – European Association of Nuclear Medicine – congress (Vienna, October 17-21, 2020).

About MEDDraysintell

MEDDraysintell is a team of international experts providing first-rate strategic intelligence in nuclear medicine, radiotherapy, proton therapy and brachytherapy. We offer the most comprehensive set of reports and directories, with around 3,700 pages of unrivaled intelligence covering some of the most exciting healthcare technologies using radiation for diagnosis and treatment. We offer client-specific intelligence in the field of radiation healthcare, with the upmost knowledge leveraging our extended network of worldwide contacts. We are proud to support numerous companies globally, helping them to better understand the markets, the competitive environment as well as the potential of merger and acquisitions (M&A) and technology development. We have repeat satisfied clients operating in the field of medical radiation, investment banks and institutional investors, large international consulting firms and university research laboratories. MEDDraysintell was created in 2013 by Paul-Emmanuel Goethals and Richard Zimmermann. It combines over 70 years of experience in radiation healthcare. www.meddraysintell.com

Contact

Paul-Emmanuel Goethals, MBA
Louvain-la-Neuve, Belgium
e-Mail: peg@meddraysintell.com
Mobile: +32 491 080 968

Richard Zimmermann, PhD
Lalaye, France
e-Mail: rz@meddraysintell.com
Mobile: +33 6 82 80 06 00